Essential Tremor Pipeline Insight

DelveInsight’s, “Essential Tremor – Pipeline Insight, 2022,” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Essential Tremor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Geography Covered

  • Global coverage

Essential Tremor Understanding

Essential Tremor: Overview

Essential tremor (ET) is a progressive, neurological disease characterized by tremor, most often of the hands or arms. A tremor is an involuntary, rhythmic, movement of a body part. Tremor may be seen as involuntary shaking or trembling of the affected area. In individuals with ET, other motor symptoms may be present including an unsteady manner of walking due to an inability to coordinate voluntary movements (ataxia). In some cases, affected individuals may also develop a variety of non-motor symptoms including cognitive impairment, depression or anxiety. ET can occur in childhood or adulthood. The exact, underlying cause of ET is not fully understood. In some cases, the disorder runs in families; in others, it occurs in individuals with no previous family history. The causes of ET are most likely many, which means that several factors, such as genetic and environmental ones, may each play a role in the development of the disorder.


"Essential Tremor - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Essential Tremor pipeline landscape is provided which includes the disease overview and Essential Tremor treatment guidelines. The assessment part of the report embraces, in depth Essential Tremor commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Essential Tremor collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Essential Tremor R&D. The therapies under development are focused on novel approaches to treat/improve Essential Tremor.

Essential Tremor Emerging Drugs Chapters

This segment of the Essential Tremor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.


Essential Tremor Emerging Drugs


SAGE-324: Sage therapeutics

SAGE-324 is an investigational oral neuroactive steroid (NAS) GABAA receptor positive allosteric modulator (PAM). NAS GABAA receptor PAMs bind to both synaptic and extrasynaptic GABAA receptors, enhancing inhibitory activity of the GABAergic system, the major inhibitory neurotransmission system in the brain. GABA is the primary inhibitory neurotransmitter in the central nervous system and plays a critical role in maintaining balanced neuronal activity in the brain. GABA dysregulation has been implicated in the pathophysiology of ET. It is currently being evaluated in Phase II stage of development.


PRAX-944: Praxis Precision Medicines

PRAX-944, a potentially differentiated selective small molecule inhibitor of T-type calcium channels, for the treatment of Essential Tremor, or ET. Praxis is currently in the second of two cohorts of its PRAX-944 Phase 2a trial for treatment of essential tremor (ET), evaluating safety and efficacy in patients titrated up to 120 mg per day.

Further product details are provided in the report……..

Essential Tremor: Therapeutic Assessment

This segment of the report provides insights about the different Essential Tremor drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Essential Tremor

There are approx. 8+ key companies which are developing the therapies for Essential Tremor. The companies which have their Essential Tremor drug candidates in the most advanced stage, i.e. Phase II include, Sage therapeutics.


DelveInsight’s report covers around 8+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration


Essential Tremor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type


Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Essential Tremor: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Essential Tremor therapeutic drugs key players involved in developing key drugs.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Essential Tremor drugs.

Essential Tremor Report Insights

  • Essential Tremor Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Essential Tremor Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Essential Tremor drugs?
  • How many Essential Tremor drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Essential Tremor?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Essential Tremor therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Essential Tremor and their status?
  • What are the key designations that have been granted to the emerging drugs?


Executive Summary

Essential Tremor: Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Mid Stage Products (Phase II)

  • Comparative Analysis

SAGE-324: Sage therapeutics

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Preclinical Stage Products

  • Comparative Analysis

TD 567: OB Pharmaceuticals

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Essential Tremor Key Companies

Essential Tremor Key Products

Essential Tremor- Unmet Needs

Essential Tremor- Market Drivers and Barriers

Essential Tremor- Future Perspectives and Conclusion

Essential Tremor Analyst Views

Essential Tremor Key Companies


List of Table

Table 1: Total Products for Essential Tremor

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type                                              

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Essential Tremor

Figure 2: Late Stage Products                             

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type                                                                       

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Product

• Sage Therapeutics
• Praxis Precision Medicines
• Cadent Therapeutics
• Jazz Pharmaceuticals
• Praxis Precision Medicines
• Neurocrine Biosciences
• Merz Pharma
• OB Pharmaceuticals


Forward to Friend

Need A Quote